Evidence map›Paper›PMID 42016169›Full record

ArticleiScience2026

Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans.

Daniel J Schuster, Shuying S Li, Dieter Mielke, Kelly E Seaton, Caroline Brackett, Kan Li, Xiaoying Shen, Martina S Wesley, Nathan Eisel, Nicole L Yates and 20 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Daniel J SchusterCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Shuying S LiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Dieter MielkeCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Kelly E SeatonCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Caroline BrackettCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Kan LiCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Xiaoying ShenCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Martina S WesleyCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Nathan EiselCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Nicole L YatesCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Lu ZhangCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Sheetal SawantCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kristen W CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sherry Stanfield-OakleyDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Anton M SholukhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Russell St GermainVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Xiaohong LiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jiani HuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Jorge A Gallardo-CartagenaUniversidad Nacional Mayor de San Marcos, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Lima, Peru.
April Kaur RandhawaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
S Moses DennisonCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
John A HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shelly KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Ollivier HyrienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Georgia D TomarasCenter for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

SARS-CoV-2 acquisition induces a spectrum of COVID-19 disease severity and duration among people. Prolonged viral antigen shedding (PVS) is defined as when a person tests positive by direct antigen tests performed a minimum of 21 days apart. It is unclear why some people exhibit delayed SARS-CoV-2 viral antigen clearance. In this cross-sectional observational study enrolling vaccine naive adults from the USA and Peru following recovery from SARS-CoV-2 acquisition, we examined a suite of blood-derived immune measures to understand differences between participants with PVS (

Indexed as

Health sciencesImmunologyVirology

Identifiers

PMID42016169
PMCPMC13092704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.